ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Celltrion and Samsung Bioepis side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

CelltrionSamsung Bioepis
studies on the registry8433
open to participants now42
phase 3 studies under way51
reach primary completion within a year61
programswith a study of their own in two years154

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseCelltrionSamsung Bioepis
Phase 1

Celltrion: 6 of its 15 programs at phase 1

  1. ixekizumabphase 1
  2. L03RD1phase 1
  3. L03RD2phase 1
  4. CT-P52phase 1
  5. CTL02phase 1

and 1 more — sign in to see them all

40%

Samsung Bioepis: 2 of its 4 programs at phase 1

  1. ixekizumabphase 1
  2. potassium L-ascorbatephase 1
50%
Phase 200%

Samsung Bioepis: 2 of its 4 programs at phase 2

  1. Ranibizumabphase 2
  2. afliberceptphase 2
50%
Phase 3

Celltrion: 9 of its 15 programs at phase 3

  1. CT-P55phase 3
  2. CT-P51phase 3
  3. daratumumabphase 3
  4. empagliflozinphase 3
  5. CT-P43phase 3

and 4 more — sign in to see them all

60%
00%
Approved, new studies00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Celltrion3 readouts · 3 phase 3·

Celltrion, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. empagliflozinphase 3 · Dec 0 · NCT07093476
·

Celltrion, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. CT-P51phase 3 · Feb 0 · NCT06939595

Celltrion, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. daratumumabphase 3 · Mar 8 · NCT06952478
·······
Samsung Bioepis1 readouts · 0 phase 3·······

Samsung Bioepis, Jun ’27: 1 program whose next study reaches primary completion

  1. ixekizumabphase 1 · Jun 9 · NCT07789964
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Celltrion

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Samsung Bioepis

New programs 1

  • afliberceptphase 2 · first study · Sep 21 · Macular Degeneration

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionCelltrionSamsung Bioepis
Psoriasisboth · compare here

Celltrion in Psoriasis: 3 programs

  1. CT-P55phase 3
  2. CT-P43phase 3
  3. ixekizumabphase 1

Their studies: Celltrion’s studies of Psoriasis in search

Samsung Bioepis in Psoriasis: 1 program

  1. ixekizumabphase 1

Their studies: Samsung Bioepis’s studies of Psoriasis in search

Arthritis, Rheumatoidboth · compare here

Celltrion in Arthritis, Rheumatoid: 2 programs

  1. CT-P13 SC Auto-Injectorphase 3
  2. ixekizumabphase 1

Their studies: Celltrion’s studies of Arthritis, Rheumatoid in search

Samsung Bioepis in Arthritis, Rheumatoid: 1 program

  1. ixekizumabphase 1

Their studies: Samsung Bioepis’s studies of Arthritis, Rheumatoid in search

Arthritis, Psoriaticboth · compare here

Celltrion in Arthritis, Psoriatic: 1 program

  1. ixekizumabphase 1

Their studies: Celltrion’s studies of Arthritis, Psoriatic in search

Samsung Bioepis in Arthritis, Psoriatic: 1 program

  1. ixekizumabphase 1

Their studies: Samsung Bioepis’s studies of Arthritis, Psoriatic in search

Axial Spondyloarthritisboth · compare here

Celltrion in Axial Spondyloarthritis: 1 program

  1. ixekizumabphase 1

Their studies: Celltrion’s studies of Axial Spondyloarthritis in search

Samsung Bioepis in Axial Spondyloarthritis: 1 program

  1. ixekizumabphase 1

Their studies: Samsung Bioepis’s studies of Axial Spondyloarthritis in search

Spondylarthritisboth · compare here

Celltrion in Spondylarthritis: 1 program

  1. ixekizumabphase 1

Their studies: Celltrion’s studies of Spondylarthritis in search

Samsung Bioepis in Spondylarthritis: 1 program

  1. ixekizumabphase 1

Their studies: Samsung Bioepis’s studies of Spondylarthritis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetCelltrionSamsung Bioepis
IL17Aixekizumabruleixekizumabrule
A target, or a pathogen for a vaccine, known for: Celltrion 6 of 15 · Samsung Bioepis 3 of 4 programs (9 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.